157 related articles for article (PubMed ID: 37246087)
41. MYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma.
Hamadeh F; MacNamara SP; Aguilera NS; Swerdlow SH; Cook JR
Mod Pathol; 2015 Apr; 28(4):564-74. PubMed ID: 25216226
[TBL] [Abstract][Full Text] [Related]
42. Detection of the MYD88
Wu YY; Jia MN; Cai H; Qiu Y; Zhou DB; Li J; Cao XX
Ann Hematol; 2020 Aug; 99(8):1763-1769. PubMed ID: 32577844
[TBL] [Abstract][Full Text] [Related]
43. Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.
Treon SP; Xu L; Guerrera ML; Jimenez C; Hunter ZR; Liu X; Demos M; Gustine J; Chan G; Munshi M; Tsakmaklis N; Chen JG; Kofides A; Sklavenitis-Pistofidis R; Bustoros M; Keezer A; Meid K; Patterson CJ; Sacco A; Roccaro A; Branagan AR; Yang G; Ghobrial IM; Castillo JJ
J Clin Oncol; 2020 Apr; 38(11):1198-1208. PubMed ID: 32083995
[TBL] [Abstract][Full Text] [Related]
44. The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia.
Tadic L; Marjanovic G; Macukanovic-Golubovic L; Krstic M; Jevtovic-Stoimenov T; Kostov M; Smelcerovic Z; Stojanovic M
J BUON; 2016; 21(5):1259-1267. PubMed ID: 27837631
[TBL] [Abstract][Full Text] [Related]
45. Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
Chakraborty R; Kapoor P; Ansell SM; Gertz MA
Expert Rev Anticancer Ther; 2015; 15(10):1143-56. PubMed ID: 26196236
[TBL] [Abstract][Full Text] [Related]
46. Waldenström macroglobulinemia.
Treon SP; Hunter ZR; Castillo JJ; Merlini G
Hematol Oncol Clin North Am; 2014 Oct; 28(5):945-70. PubMed ID: 25212891
[TBL] [Abstract][Full Text] [Related]
47. How to Sequence Therapies in Waldenström Macroglobulinemia.
Sarosiek S; Treon SP; Castillo JJ
Curr Treat Options Oncol; 2021 Aug; 22(10):92. PubMed ID: 34426943
[TBL] [Abstract][Full Text] [Related]
48. Preneoplastic somatic mutations including
Rodriguez S; Celay J; Goicoechea I; Jimenez C; Botta C; Garcia-Barchino MJ; Garces JJ; Larrayoz M; Santos S; Alignani D; Vilas-Zornoza A; Perez C; Garate S; Sarvide S; Lopez A; Reinhardt HC; Carrasco YR; Sanchez-Garcia I; Larrayoz MJ; Calasanz MJ; Panizo C; Prosper F; Lamo-Espinosa JM; Motta M; Tucci A; Sacco A; Gentile M; Duarte S; Vitoria H; Geraldes C; Paiva A; Puig N; Garcia-Sanz R; Roccaro AM; Fuerte G; San Miguel JF; Martinez-Climent JA; Paiva B
Sci Adv; 2022 Jan; 8(3):eabl4644. PubMed ID: 35044826
[TBL] [Abstract][Full Text] [Related]
49. Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells.
Sewastianik T; Guerrera ML; Adler K; Dennis PS; Wright K; Shanmugam V; Huang Y; Tanton H; Jiang M; Kofides A; Demos MG; Dalgarno A; Patel NA; Nag A; Pinkus GS; Yang G; Hunter ZR; Jarolim P; Munshi NC; Treon SP; Carrasco RD
Blood Adv; 2019 Nov; 3(21):3360-3374. PubMed ID: 31698464
[TBL] [Abstract][Full Text] [Related]
50. How I treat Waldenström macroglobulinemia.
Treon SP
Blood; 2015 Aug; 126(6):721-32. PubMed ID: 26002963
[TBL] [Abstract][Full Text] [Related]
51. MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival.
Treon SP; Gustine J; Xu L; Manning RJ; Tsakmaklis N; Demos M; Meid K; Guerrera ML; Munshi M; Chan G; Chen J; Kofides A; Patterson CJ; Yang G; Liu X; Severns P; Dubeau T; Hunter ZR; Castillo JJ
Br J Haematol; 2018 Feb; 180(3):374-380. PubMed ID: 29181840
[TBL] [Abstract][Full Text] [Related]
52.
Yu X; Li W; Deng Q; Li L; Hsi ED; Young KH; Zhang M; Li Y
Cancer Res; 2018 May; 78(10):2457-2462. PubMed ID: 29703722
[TBL] [Abstract][Full Text] [Related]
53. MYD88 L265P mutation in Waldenstrom macroglobulinemia.
Poulain S; Roumier C; Decambron A; Renneville A; Herbaux C; Bertrand E; Tricot S; Daudignon A; Galiègue-Zouitina S; Soenen V; Theisen O; Grardel N; Nibourel O; Roche-Lestienne C; Quesnel B; Duthilleul P; Preudhomme C; Leleu X
Blood; 2013 May; 121(22):4504-11. PubMed ID: 23532735
[TBL] [Abstract][Full Text] [Related]
54. A new era for Waldenstrom macroglobulinemia: MYD88 L265P.
Treon SP; Hunter ZR
Blood; 2013 May; 121(22):4434-6. PubMed ID: 23723443
[TBL] [Abstract][Full Text] [Related]
55. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms.
Varettoni M; Arcaini L; Zibellini S; Boveri E; Rattotti S; Riboni R; Corso A; Orlandi E; Bonfichi M; Gotti M; Pascutto C; Mangiacavalli S; Croci G; Fiaccadori V; Morello L; Guerrera ML; Paulli M; Cazzola M
Blood; 2013 Mar; 121(13):2522-8. PubMed ID: 23355535
[TBL] [Abstract][Full Text] [Related]
56. Gamma heavy chain disease lacks the MYD88 L265p mutation associated with lymphoplasmacytic lymphoma.
Hamadeh F; MacNamara S; Bacon CM; Sohani AR; Swerdlow SH; Cook JR
Haematologica; 2014 Sep; 99(9):e154-5. PubMed ID: 24859878
[No Abstract] [Full Text] [Related]
57. Genetic analysis of Diffuse Large B-cell Lymphoma occurring in cases with antecedent Waldenström Macroglobulinaemia reveals different patterns of clonal evolution.
Talaulikar D; Biscoe A; Lim JH; Gibson J; Arthur C; Mackinlay N; Saxena K; Cheng YY; Chen VM
Br J Haematol; 2019 May; 185(4):767-770. PubMed ID: 30338525
[No Abstract] [Full Text] [Related]
58. Monitoring of MYD88 L265P mutation by droplet digital polymerase chain reaction for prediction of early relapse in a patient with Bing-Neel syndrome.
Shikata H; Kihara H; Kaneko M; Matsukage S; Hattori K
Int J Hematol; 2021 Apr; 113(4):586-591. PubMed ID: 33222046
[TBL] [Abstract][Full Text] [Related]
59. Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May Harbor MYD88 L265P Mutations.
King RL; Gonsalves WI; Ansell SM; Greipp PT; Frederick LA; Viswanatha DS; He R; Kyle RA; Gertz MA; Kapoor P; Morice WG; Howard MT
Am J Clin Pathol; 2016 Jun; 145(6):843-51. PubMed ID: 27329639
[TBL] [Abstract][Full Text] [Related]
60. First Latin America report on the diagnostic utility of the study of the MYD88 L265P gene mutation in patients with Waldenström Macroglobulinemia.
Giuliani F; Pavlovsky MA; Giere I; Fernandez I; Sackmann F; Pavlovsky A; Remaggi G; Castillo JJ
Ann Hematol; 2022 Oct; 101(10):2365-2367. PubMed ID: 35794278
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
